RGH-5526 is a novel antihypertensive drug. It causes an increase in hypothalamic norepinephrine (NA) turnover (utilization), and the increase in hypothalamic noradrenergic neuron activity may lead to a decrease in peripheral sympathetic nerve activity, resulting in a significant reduction in blood pressure.